The Danish pharmaceutical company Bavarian Nordic, the only manufacturer of third-generation vaccines against smallpox, announced on Tuesday the sale of 110,000 doses to the European Commission to deal with the outbreak of monkeypox, detected in fifteen countries of the EU, with Spain, Portugal, Germany and France as the most affected countries. The purchase will be channeled through the Health Emergency Preparedness and Response Authority (HERA), created in response to the coronavirus pandemic.
The Bavarian Nordic vaccine, called Imvanex in Europe and Jynneos in the United States, was initially designed to prevent traditional smallpox with fewer side effects than so-called second-generation vaccines. Serum, however, has also been shown to be effective against mono in about 85% of patients, although this percentage is calculated in old studies and experts point out that this data will probably be updated during the current outbreak.
In Europe, the vaccine is not approved against monkeypox, although in the United Kingdom it has even been used in children in previous off-label outbreaks, given its good safety profile. In the United States it is authorized for both types of smallpox.
According to the company, shipments of the first doses of the vaccine “will begin immediately and will be completed over the next few months.” “We are very pleased to sign this agreement with HERA and that our vaccine will help improve the European Union’s ability to deal with the current monkeypox outbreak,” said Bavarian Nordic President Paul Chaplin.
At the moment, the way in which the acquired doses will be distributed among the member states has not been made public. Spain is the country that most urgently needs them since, with 400 cases, it is the EU country most affected by the outbreak.
Given the lack of doses, the Ministry of Health and the communities agreed last week to start vaccinating the highest-risk contacts of positive cases, such as immunosuppressed people and health personnel who have been in contact without measures, using the ring strategy. of protection with the patient or their samples. When the number of available units increases, as discussed by the Public Health Commission, the vaccine will also be offered to all contacts within four days after the risk contact.
According to available studies, if a person exposed to the virus is vaccinated within four days, the development of the disease is prevented. If you do it in the following days, up to 13, the symptoms developed will be milder.
#European #Commission #closes #purchase #monkeypox #vaccines #member #states